HER2 status-Positive Posts on Medivizor
Navigation Menu

HER2 status-Positive Posts on Medivizor

The outcomes of trastuzumab emtansine in patients with brain metastasis from HER2-positive breast cancer

The outcomes of trastuzumab emtansine in patients with brain metastasis from HER2-positive breast cancer

Posted by on Jul 19, 2020 in Breast cancer | 0 comments

In a nutshell The study evaluated the effects of trastuzumab emtansine (T-DM1; Kadcyla) to treat patients with brain metastasis (BM) from HER2-positive metastatic breast cancer (mBC). The main finding was that T-DM1 was safe and effective in such patients. Some background HER-2 positive mBC cells have an excess of the HER-2 protein. Such cancers...

Read More

Long-term outcomes of pertuzumab added to trastuzumab and docetaxel treatment for patients with advanced HER2-positive breast cancer

Posted by on Apr 7, 2020 in Breast cancer | 0 comments

In a nutshell This study looked at whether pertuzumab (Perjeta) benefits patients with metastatic HER2-positive breast cancer when added to trastuzumab (Herceptin) and docetaxel (Taxotere) treatment. They found that adding pertuzumab improved long-term patient outcomes. Some background Breast cancer can now be tested for some of the signals involved...

Read More

Searching for patients with early-stage HER2+ breast cancer to trial a new treatment regime

Posted by on Apr 24, 2019 in Breast cancer | 0 comments

In a nutshell This study will examine how safe and effective the medication atezolizumab (Tecentriq) is in combination with other anti-cancer medicines for treating early stage HER2+ breast cancer. The main outcome that will be measured is how many patients completely respond to treatment, with no trace of the cancer remaining. The details...

Read More

Searching for patients with HER2 positive breast cancer that has spread to trial a new treatment

Posted by on Feb 23, 2019 in Breast cancer | 0 comments

In a nutshell This trial aims to see if combining two medications, T-DM1 (Kadcycla) and palbociclib (Ibrance) is better than just using T-DM1 in treating HER2+ breast cancer that has spread. The main outcome that will be measured is survival without the cancer growing or spreading. The study is being conducted in Arizona, the United States.  The...

Read More

Adding pertuzumab to treatment in breast cancer

Posted by on Dec 4, 2018 in Breast cancer | 0 comments

In a nutshell This study wanted to find out which treatment is better for breast cancer, chemotherapy plus trastuzumab (Herceptin) and surgery, or pertuzumab (Perjeta), and chemotherapy plus trastuzumab (Herceptin) and surgery. The study found that adding pertuzumab to the standard treatment worked better to completely remove all signs of cancer compared...

Read More

Comparison of lapatinib and trastuzumab in patients with HER-2 receptor positive breast cancer

Posted by on Jul 2, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to compare lapatinib (Tykerb) and trastuzumab (Herceptin) in patients with HER-2 receptor positive breast cancer. This study found that in patients with hormone receptor-positive tumors, use of lapatinib for 6 months, followed by trastuzumab for 12 months significantly improved survival...

Read More

Looking for patients with HER2-positive inoperable breast cancer to examine the efficacy and safety of antibody-drug conjugate SYD985

Posted by on Feb 3, 2018 in Breast cancer | 0 comments

In a nutshell This trial is examining the effectiveness of the antibody-drug conjugate SYD985 for HER2-positive inoperable advanced breast cancer. The main outcome to be measured will be time from treatment until disease progression or the time taken for tumor growth or spread. This study is being conducted in Baltimore, Maryland, inthe United...

Read More